Innovative Approaches to Optimize the Therapeutic Benefit of Autophagy Inhibition

Case ID:

This invention is a set of novel synthetic compounds that demonstrate autophagy-inhibiting efficacy, useful for cancer and pulmonary hypertension treatment.



Autophagy is an evolutionarily conserved lysosomal protein degradation process. Aberrant autophagy plays a role in the pathogenesis of many health conditions including cancer, pulmonary hypertension, diabetes, neurodegenerative disorders, and others. This technology is directed to a series of novel therapeutic compounds that inhibit autophagy.



  • Autophagy inhibitors for cancer
  • Autophagy inhibitors for pulmonary hypertension



  • Novel
  • Potential to slow disease pathogenesis
  • Ability to treat a wide array of pulmonary arterial hypertension (PAH)
Patent Information:
Contact For More Information:
Mitch Graffeo
Sr. Licensing Manager - COM-T
The University of Arizona
Lead Inventor(s):
Jennifer Carew
Steffan Nawrocki
Wei Wang